CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma.
B-cell lymphoma
CAR T-cell persistence
CAR T-cell therapy
ddPCR
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Mar 2023
16 Mar 2023
Historique:
received:
12
02
2023
revised:
10
03
2023
accepted:
13
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Chimeric antigen receptor (CAR) T-cell therapy has led to profound and durable tumor responses in a relevant subset of patients with relapsed/refractory (r/r) B-cell lymphomas. Still, some patients show insufficient benefit or relapse after CAR T-cell therapy. We performed a retrospective study to investigate the correlation between CAR T-cell persistence in the peripheral blood (PB) at 6 months, assessed by droplet digital PCR (ddPCR), with CAR T-cell treatment outcome. 92 patients with r/r B-cell lymphomas were treated with CD19-targeting CAR T-cell therapies at our institution between 01/2019-08/2022. Six months post-treatment, 15 (16%) patients had no detectable circulating CAR-T constructs by ddPCR. Patients with CAR T-cell persistence had a significantly higher CAR T-cell peak (5432 vs. 620 copies/ug cfDNA,
Identifiants
pubmed: 36982764
pii: ijms24065688
doi: 10.3390/ijms24065688
pmc: PMC10056741
pii:
doi:
Substances chimiques
cell-associated neurotoxicity
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-20
pubmed: 33989023
Nature. 2022 Feb;602(7897):503-509
pubmed: 35110735
Cancers (Basel). 2020 Jul 20;12(7):
pubmed: 32698364
Front Immunol. 2020 May 12;11:888
pubmed: 32477359
Blood Cancer Discov. 2021 Jul;2(4):302-318
pubmed: 34386775
Int J Mol Sci. 2022 Jul 08;23(14):
pubmed: 35886920
Cancer Med. 2021 Feb;10(3):999-1011
pubmed: 33382529
Cancers (Basel). 2022 May 20;14(10):
pubmed: 35626120
Curr Opin Oncol. 2020 Sep;32(5):408-417
pubmed: 32740094
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
AAPS J. 2021 Mar 2;23(2):36
pubmed: 33655393
N Engl J Med. 2021 Feb 18;384(7):673-674
pubmed: 33596362
Biol Blood Marrow Transplant. 2019 Nov;25(11):e344-e351
pubmed: 31279751
Blood Adv. 2021 Apr 27;5(8):2128-2136
pubmed: 33881465
Mol Ther. 2009 Aug;17(8):1453-64
pubmed: 19384291
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Cancers (Basel). 2022 Jul 20;14(14):
pubmed: 35884587
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Blood Adv. 2021 Jun 8;5(11):2523-2527
pubmed: 34100900
Clin Cancer Res. 2018 Dec 15;24(24):6175-6184
pubmed: 30190371
Blood Adv. 2022 Jun 28;6(12):3606-3610
pubmed: 35271707
Mol Ther Methods Clin Dev. 2018 Jan 31;8:210-221
pubmed: 29552577
Exp Hematol. 2020 Aug;88:7-14.e3
pubmed: 32673688
Oncol Lett. 2017 Sep;14(3):3803-3808
pubmed: 28927150
Expert Opin Biol Ther. 2020 Jun;20(6):653-664
pubmed: 32067497
Curr Probl Cancer. 2022 Feb;46(1):100826
pubmed: 35012754
Am J Hematol. 2019 May;94(S1):S3-S9
pubmed: 30680780
Cancer Immunol Res. 2019 May;7(5):759-772
pubmed: 30890531
Cancers (Basel). 2020 Nov 19;12(11):
pubmed: 33228221
Blood Adv. 2021 Jul 27;5(14):2799-2806
pubmed: 34264268
Mol Ther Methods Clin Dev. 2020 Jan 15;16:172-178
pubmed: 32055645
Eur J Immunol. 2021 Sep;51(9):2151-2163
pubmed: 34196410
Cancers (Basel). 2021 Jul 14;13(14):
pubmed: 34298748
J Transl Med. 2020 May 8;18(1):191
pubmed: 32384903
Front Med (Lausanne). 2022 Nov 03;9:1042501
pubmed: 36405594
Immunity. 2016 Feb 16;44(2):380-90
pubmed: 26885860
Blood. 2017 Nov 23;130(21):2317-2325
pubmed: 28935694
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33846220
Nat Rev Clin Oncol. 2019 Jun;16(6):372-385
pubmed: 30837712
Int J Mol Sci. 2022 Nov 01;23(21):
pubmed: 36362130
Oncologist. 2020 Feb;25(2):e321-e327
pubmed: 32043764
J Neurol. 2021 Apr;268(4):1544-1554
pubmed: 33140239
Front Mol Biosci. 2020 May 15;7:84
pubmed: 32500079
Ir J Med Sci. 2021 Feb;190(1):41-57
pubmed: 32607912
Blood Adv. 2020 Nov 24;4(22):5607-5615
pubmed: 33180899
Int J Mol Sci. 2021 Oct 07;22(19):
pubmed: 34639168
Nat Rev Drug Discov. 2019 Sep;18(9):663-664
pubmed: 31477855
Mol Ther Oncolytics. 2020 Jun 24;18:272-281
pubmed: 32728615